These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 12435687)
21. Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans. Nussbaumer-Pröll A; Matzneller P; Eberl S; Zeitlinger M Eur J Clin Microbiol Infect Dis; 2024 May; 43(5):927-936. PubMed ID: 38483681 [TBL] [Abstract][Full Text] [Related]
22. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Ernst EJ; Klepser ME; Pfaller MA Antimicrob Agents Chemother; 2000 Apr; 44(4):1108-11. PubMed ID: 10722525 [TBL] [Abstract][Full Text] [Related]
23. Examination of the in vitro fungicidal activity of echinocandins against Candida lusitaniae by time-killing methods. Cantón E; Pemán J; Hervás D; Espinel-Ingroff A J Antimicrob Chemother; 2013 Apr; 68(4):864-8. PubMed ID: 23228935 [TBL] [Abstract][Full Text] [Related]
24. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Clancy CJ; Huang H; Cheng S; Derendorf H; Nguyen MH Antimicrob Agents Chemother; 2006 Jul; 50(7):2569-72. PubMed ID: 16801448 [TBL] [Abstract][Full Text] [Related]
25. Post-antifungal effects and time-kill studies of anidulafungin, caspofungin, and micafungin against Candida glabrata and Candida parapsilosis. Smith RP; Baltch A; Bopp LH; Ritz WJ; Michelsen PP Diagn Microbiol Infect Dis; 2011 Oct; 71(2):131-8. PubMed ID: 21865002 [TBL] [Abstract][Full Text] [Related]
26. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp. Serena C; Mariné M; Quindós G; Carrillo AJ; Cano JF; Pastor FJ; Guarro J Antimicrob Agents Chemother; 2008 Apr; 52(4):1529-32. PubMed ID: 18227181 [TBL] [Abstract][Full Text] [Related]
27. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851 [TBL] [Abstract][Full Text] [Related]
28. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Scorneaux B; Angulo D; Borroto-Esoda K; Ghannoum M; Peel M; Wring S Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069658 [TBL] [Abstract][Full Text] [Related]
29. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464 [TBL] [Abstract][Full Text] [Related]
30. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Pai MP; Jones AL; Mullen CK Diagn Microbiol Infect Dis; 2007 May; 58(1):129-32. PubMed ID: 17240112 [TBL] [Abstract][Full Text] [Related]
31. [In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species.]. Choi HW; Shin JH; Lee JS; Cho D; Shin MG; Suh SP; Ryang DW Korean J Lab Med; 2006 Aug; 26(4):275-81. PubMed ID: 18156738 [TBL] [Abstract][Full Text] [Related]
32. Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum. Kovács R; Saleh Q; Bozó A; Tóth Z; Gesztelyi R; Kardos T; Kardos G; Takacs I; Majoros L Mycopathologia; 2017 Dec; 182(11-12):979-987. PubMed ID: 28699056 [TBL] [Abstract][Full Text] [Related]
33. [The fungicidal activity and paradoxical effect of caspofungin against yeast. Influence of culture medium and incubation time]. Cantón E; Pemán J; Romero M; Valentín A; Gobernado M Rev Esp Quimioter; 2007 Dec; 20(4):433-41. PubMed ID: 18563217 [TBL] [Abstract][Full Text] [Related]
34. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Pfaller MA; Diekema DJ; Messer SA; Hollis RJ; Jones RN Antimicrob Agents Chemother; 2003 Mar; 47(3):1068-71. PubMed ID: 12604543 [TBL] [Abstract][Full Text] [Related]
35. Time-kill studies investigating the killing activity of caspofungin against Candida dubliniensis: comparing RPMI-1640 and antibiotic medium 3. Varga I; Sóczó G; Kardos G; Majoros L J Antimicrob Chemother; 2008 Jul; 62(1):149-52. PubMed ID: 18390882 [TBL] [Abstract][Full Text] [Related]
36. The echinocandins. Cappelletty D; Eiselstein-McKitrick K Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149 [TBL] [Abstract][Full Text] [Related]
37. Decreased Killing Activity of Micafungin Against Candida guilliermondii, Candida lusitaniae, and Candida kefyr in the Presence of Human Serum. Saleh Q; Kovács R; Kardos G; Gesztelyi R; Kardos T; Bozó A; Majoros L Microb Drug Resist; 2017 Sep; 23(6):764-770. PubMed ID: 28072553 [TBL] [Abstract][Full Text] [Related]
38. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Jacobsen MD; Whyte JA; Odds FC Antimicrob Agents Chemother; 2007 May; 51(5):1882-4. PubMed ID: 17307974 [TBL] [Abstract][Full Text] [Related]
39. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Cantón E; Pemán J; Sastre M; Romero M; Espinel-Ingroff A Antimicrob Agents Chemother; 2006 Aug; 50(8):2829-32. PubMed ID: 16870779 [TBL] [Abstract][Full Text] [Related]
40. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital]. Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]